Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409699 | SCV000485328 | likely pathogenic | Deficiency of butyryl-CoA dehydrogenase | 2015-11-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000409699 | SCV003484002 | pathogenic | Deficiency of butyryl-CoA dehydrogenase | 2022-03-23 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs541587321, gnomAD 0.007%). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the ACADS protein in which other variant(s) (p.Arg386Cys) have been determined to be pathogenic (PMID: 16906473; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 370099). This variant has not been reported in the literature in individuals affected with ACADS-related conditions. This sequence change creates a premature translational stop signal (p.Gln362*) in the ACADS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 51 amino acid(s) of the ACADS protein. |